Calls for papers
-
According to Insmed, the Phase 3b ENCORE study of once-daily Arikayce amikacin liposome inhalation suspension plus azithromycin and ethambutol in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection met its primary endpoint. The study demonstrated a… Read more . . .
-
CDMO Experic and particle engineering specialist Flurry Powders have announced a partnership to offer development services for inhaled and nasal drug formulations that require specialized particle engineering and manufacturing. The companies cite potential opportunities for dry… Read more . . .
-
Interna Therapeutics has announced that under an agreement with the University of Oxford researchers led by Oxford’s Helen McShane will conduct a Phase 2a study of the company’s intranasal molecular nano-motor (MNM)-siRNA drug against SARS-CoV-2.… Read more . . .
-
Nexalis Therapeutics, which recently changed its name from InhaleRx, has announced the initiation of a Phase 1 trial of its IRX-616a cannabidiol MDI, which the company is developing for the treatment of panic disorder. In… Read more . . .
-
Zydus Lifesciences has announced the launch of a foldable MDI spacer after acquiring marketing and commercialization rights to the device from Mumbai-based AeroDel Technology Innovations. The spacer, which AeroDel calls A202, is being marketed by… Read more . . .
-
Inhaled drug developer Transpire Bio announced that it has hired Ewan Livesey as Head of Business Development. Livesey has more than 30 years experience in business and corporate development and has served in a number… Read more . . .
-
Nasus Pharma announced that topline data from its Phase 2 trial of NS002 intranasal dry powder epinephrine versus EpiPen intramuscular epinephrine “demonstrated multiple significant advantages for NS002 across key pharmacokinetic and pharmacodynamic parameters.” The company… Read more . . .
-
Australian biopharm Covirix Medical, which is developing a broad-spectrum antiviral, has signed a letter of intent with Aptar Pharma for a feasibility study evaluating delivery of the antiviral via Aptar’s Orbital dry powder inhaler. The… Read more . . .
-
Nuance Pharma announced that the Hong Kong Drug Office has approved Ohtuvayre ensifentrine inhalation suspension for the treatment of COPD. According to Nuance, Ohtuvarye had been available through certain medical facilities in Macau and Hong Kong… Read more . . .
-
Orbia Fluor & Energy Materials (previously Koura, Mexichem) has announced the submission of a drug master file for its HFA 152a MDI propellant, marketed as Zephex 152a. The company kicked off the transition to low global warming potential… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK